Lauren Miller, MPAS, PA-C

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

Experts discuss key takeaways for providers in the management of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss possible treatment algorithms when using tapinarof for plaque psoriasis (PP) patients.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss the clinical importance of the remittive effect in plaque psoriasis (PP) patients.

Experts discuss recent studies of novel treatments for plaque psoriasis (PP) and the importance of long-term data.

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss tapinarof as a treatment for plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss new treatments for plaque psoriasis (PP) and their mechanisms of action.

Experts discuss the landscape of topical drugs for plaque psoriasis (PP) and key factors in treatment options.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight treatment efficacy considerations for plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss how patient goals and education can inform next steps of treatment for plaque psoriasis (PP).

Experts offer insights on treatment selection and patient education for plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, offer considerations for treating pediatric patients with plaque psoriasis (PP).

Experts discuss plaque psoriasis (PP) treatment options for people who are or may become pregnant.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight comorbidities that caregivers should consider when treating patients with plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss key factors to consider for plaque psoriasis (PP) treatment.

Experts discuss the role and importance of physician assistants in the treatment and care of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss the symptoms of plaque psoriasis (PP) and why it may be difficult to diagnose.